- Adding bevacizumab (BVZ) to front-line chemotherapy improved PFS in patients with stage III-IV ovarian cancer irrespective of residual disease.
- BVZ improved OS in high-risk patients.
Why this matters
- Findings suggest add-on BVZ can further improve PFS in patients with residual disease after complete resection.
- In phase 3 ICON7 trial, 1528 patients with stage IIB-IV or high-risk stage I-IIA ovarian cancer were randomly assigned to receive 6 cycles of carboplatin+paclitaxel either alone or with BVZ, followed by 12 cycles of BVZ alone.
- Funding: F. Hoffmann-La Roche Ltd.
- Median duration of follow-up was 28 months for PFS and 49 months for OS.
- Add-on BVZ improved PFS in subgroups:
- Stage III: HR, 0.85; 95% CI, 0.73-0.99.
- Stage IV: HR, 0.70; 95% CI, 0.52-0.95.
- Stage IIIB-IV with no visible disease: HR, 0.77; 95% CI, 0.59-0.99.
- Stage IIIB-IV and visible residuum HR, 0.81; 95% CI, 0.69-0.95.
- No PFS benefit was seen with BVZ in stage I/II disease.
- BVZ significantly improved OS in high-risk patients (HR, 0.78; 95% CI, 0.63-0.97), but not in intent-to-treat population or other subgroups.
- Safety results in analyzed subgroups were consistent with the overall population.
- Post hoc analysis.